How to Check If the Immune System Still Recognises the Tumour Before Starting Immunotherapy

Read full text Summarise with VIRAT
Authors: Raimo van der Klein
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Checkpoint inhibitor therapy fails in the majority of cancer patients. This paper proposes that immune exhaustion conflates two mechanistically distinct states: Withdrawal (recognition intact, action blocked) and Confusion (recognition decayed). We validate this across five single-cell datasets, four cancer types, and 302 patients. In BCC, pre-treatment exhaustion is 5.6× higher in responders. In melanoma, TCF7+ revivable exhaustion is 1.77× higher in responders (84.2% accuracy). In CRC, baseline Tex is 4.4× higher in patients whose tumours clear. In NSCLC (242 patients), post-treatment direction reverses as predicted, with CCR8+ Tregs 2.7× in non-responders. We propose a five-biomarker panel with clinical instructions.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers T-cell and B-cell Immunology Immunotherapy and Immune Responses

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
19 March 2026
Language
EN
Document type
Preprint